

Rev03
 Update: Aug,08,2025
DATASHEET


HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer, His & Avi, Human

Cat. No.: Z06580


Product Introduction

Species	Human
Protein Construction	<div style="display: flex; align-items: center; justify-content: space-between;"> <div style="background-color: #0056b3; color: white; padding: 5px; text-align: center;"> HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer[Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and SLLMWITQC peptide] Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&SLLMWITQC </div> <div style="background-color: #90c090; padding: 5px; text-align: center;">His</div> <div style="background-color: #4f81bd; padding: 5px; text-align: center;">Avi</div> </div> <div style="display: flex; justify-content: space-between; margin-top: 5px;"> N-term C-term </div>
Purity	> 95% as determined by BisTris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per µg by the LAL method.
Biological Activity	Measured by its binding ability in a functional ELISA. Immobilized HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer, His & Avi, Human at 5µg/ml (100µl/well) on the plate can bind Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System	E.coli
Theoretical Molecular Weight	258 kDa
Apparent Molecular Weight	The protein migrates to 120-180 kDa (HLA-A*02:01&streptavidin tetramer) and 11.9 kDa (B2M) based on Bis-Tris PAGE result under Non reducing (N) condition.
Formulation	Lyophilized from 0.22 µm filtered solution in 20mM Tris, 150mM NaCl (pH 8.0).
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples




HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.



Log Anti-HLA-A*02:01&B2M&NY-ESO-1 Antibody, hFc Tag Conc. ($\mu\text{g/ml}$)

Immobilized HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer, His & Avi, Human, His Tag at 5 $\mu\text{g/ml}$ (100 $\mu\text{l/well}$) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&NY-ESO-1 Antibody, hFc Tag with the EC50 of 1.9 ng/ml determined by ELISA.



The purity of HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

Background

Target Background : NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.

Synonyms : MHC; MY-ESO-1; CT6.1; LAGE-2; CTAG1; CTAG1B; ESO1CTAG; LAGE2A; NY-ESO-1; CTAG1A

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

Confidential and Privileged



Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China

GenScript USA, Inc.

860 Centennial Ave. Piscataway, NJ 08854

Tel: 1-732-885-9188